David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most ...

The company also raised its quarterly dividend 15% amid rapid growth fueled in part by the blockbuster weight-loss drug ...

An innovative combination of readily available natural products has shaped up to be an alternative to drugs like Ozempic to ...

Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...

Drugmaker Eli Lilly plans to invest $3 billion to expand a manufacturing facility in the Kenosha County, Wis., to meet ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Obesity can be deadly for people living with it, but we have potential treatments that can lead to weight loss and ...

Despite risks related to early-stage IP and low trading volume, SKYE's promising IP and near-term catalysts justify a ...

Doctors might be slow to admit it, but Ozempic and other GLP-1 drugs are making dieting and exercise obsolete.

"Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment" was originally created and published by Clinical ...

A cross-sectional study of privately insured patients with obesity showed that the use of GLP-1 RAs soared from 2022 to 2023, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...